1. Companies

  2. SillaJen

SillaJen

SillaJen

Verified
Global oncolytic immunotherapeutic company.
Launch date
Employees
11-50 people
Market cap
KRW494.9b
Net debt
KRW34.6b
Enterprise valuation
$386m (Public information from Jun 2024)
San Francisco California (HQ)
http://sillajen.com
https://www.linkedin.com/company/sillajen-biotherapeutics-inc
Deals in current and previous year:

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
KRW2017201820192020202120222023
Revenues0000000000000000000000000000
% growth-12 %18 %(82 %)(85 %)1874 %(21 %)
EBITDA0000000000000000000000000000
% EBITDA margin(683 %)(723 %)(608 %)(1972 %)(7574 %)(464 %)(436 %)
Profit0000000000000000000000000000
% profit margin(831 %)(729 %)(1248 %)(2864 %)(6302 %)(504 %)(517 %)
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
    • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor

$0.0

round
investor

$0.0

round
N/A

N/A

IPO
Total Funding000k

Related Content

Recent News about SillaJen

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by SillaJen

Edit
Jennerex Biotherapeutics
Jennerex Biotherapeutics
ACQUISITION by SillaJen Nov 2013